One of the main challenges in drug discovery is the design of inhibitors with an appropriate balance between drug efficacy and potential adverse effects as early as possible in order to reduce the likelihood of safety issues. Selectivity of kinase inhibitors, or the lack thereof, often make it difficult to achieve good potency and pharmacokinetics without severe toxicity. For this reason, the commercial utility of kinase inhibitors has been limited to areas of acute care such as oncology…